Southeastern Cancer Study Group: breast cancer studies 1972-1982
| Autor: | Charles L. Vogel, James L. Wittliff, Richard V. Smalley, Victor A. Marcial, Melvin R. Moore, Carlos A. Perez, John Lefante, John T. Carpenter, Alfred Ketcham, Enrique Velez-Garcia, John R. Durant, Alfred A. Bartolucci |
|---|---|
| Rok vydání: | 1983 |
| Předmět: |
Oncology
Adult Cancer Research medicine.medical_specialty Time Factors medicine.medical_treatment Leucovorin Breast Neoplasms Breast cancer Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Radiology Nuclear Medicine and imaging Cyclophosphamide Mastectomy Postoperative Care Chemotherapy Radiation business.industry Cytarabine Middle Aged medicine.disease United States Radiation therapy Regimen Methotrexate Doxorubicin Vincristine Adjuvant Study Lymphatic Metastasis Adenocarcinoma Prednisone Female Fluorouracil business Adjuvant medicine.drug Follow-Up Studies |
| Zdroj: | International journal of radiation oncology, biology, physics. 9(12) |
| ISSN: | 0360-3016 |
| Popis: | During the past 10 years, the Southeastern Cancer Study Group (SECSG) has been engaged in one major adjuvant study and three major advanced disease studies for patients with adenocarcinoma of the breast. The adjuvant study is demonstrating that six months of adjuvant CMF is the therapeutic equivalent of 12 months and that post-operative irradiation is of no added therapeutic benefit. In patients with advanced disease, a low dose 5 drug combination of CMFVP induces more objective responses than single agent 5FU, but improves survival only for those patients with liver metastases when compared to the sequential use of the same 5 single agents. The three drug combination, CAF, utilizing doxorubicin, induces more objective responses than low dose CMFVP, but it does not improve overall survival. The subsets of patients with bone-only metastases, with local chest wall recurrence and with nodular lung metastases benefit from CAF in terms of a longer duration of disease control and longer duration of unmaintained remission, but have only a marginal improvement in survival. The addition of a phase active combination, CAMELEON, (i.e., sequentially alternating therapy) to CAF has not improved the duration of disease control and survival for patients with liver metastases, lymphangitic and nodular lung metastases compared to CAF. Aggressive combination chemotherapeutic approaches to patients with advanced disease provide better and longer disease and tumor control but only marginal improvements in overall survival. Adding additional agents to a maximally tolerable regimen has not improved the therapeutic outcome. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|